Abstract
Kawasaki disease (KD) is a multisystem vasculitis that leads to coronary artery damage and aneurysm formation. Elastolytic matrix metalloproteinases (MMPs) have been implicated in the pathogenesis of arterial aneurysms. To determine the relationship between circulating levels of elastolytic MMPs and development of coronary artery aneurysms in children with KD, we partnered studies done in affected children with an animal model of disease. In affected children, circulating protein levels and enzymatic activity of MMP-2 and MMP-9 did not have a statistically significant relationship with coronary artery outcome after adjusting for demographic characteristics, and clinical and laboratory features. Although matrix-degrading proteolytic activity was specific for affected mice and localized to inflamed coronary artery segments, the enzymatic activity in the systemic circulation of affected and control mice were not different. Similar to affected children, peripheral blood levels of MMP-9 enzymatic activity did not correlate with coronary artery disease in the animal model. Therefore, circulating levels of MMPs known to act locally may not be useful biomarkers of disease. This is especially relevant to enzymatic activity that is tightly regulated at multiple levels including the local tissue environment.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Abbreviations
- AAA:
-
abdominal aortic aneurysms
- CAL:
-
coronary artery lesions
- ECM:
-
extracellular matrix
- IVIG:
-
intravenous immunoglobulin
- IVMP:
-
intravenous methylprednisolone
- KD:
-
Kawasaki disease
- LCWE:
-
Lactobacillus casei cell wall extract
- MMP:
-
matrix metalloproteinase
- TIMP:
-
tissue inhibitor of metalloproteinase
References
Taubert KA, Rowley AH, Shulman ST 1994 Seven-year national survey of Kawasaki disease and acute rheumatic fever. Pediatr Infect Dis J 13: 704–708
Kawasaki T 1967 [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children] (Japanese). Arerugi 16: 178–222
Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, Shulman ST, Bolger AF, Ferrieri P, Baltimore RS, Wilson WR, Baddour LM, Levison ME, Pallasch TJ, Falace DA, Taubert KA 2004 Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 110: 2747–2771
Dajani AS, Taubert KA, Gerber MA, Shulman ST, Ferrieri P, Freed M, Takahashi M, Bierman FZ, Karchmer AW, Wilson W 1993 Diagnosis and therapy of Kawasaki disease in children. Circulation 87: 1776–1780
Kato H, Sugimura T, Akagi T, Sato N, Hashino K, Maeno Y, Kazue T, Eto G, Yamakawa R 1996 Long-term consequences of Kawasaki disease—a 10- to 21-year follow-up study of 594 patients. Circulation 94: 1379–1385
Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, Glode MP, Mason WH, Reddy V, Sanders SP, Shulman ST, Wiggins JW, Hicks RV, Fulton DR, Lewis AB, Leung DY, Colton T, Rosen FS, Melish ME 1986 The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 315: 341–347
de Zorzi A, Colan SD, Gauvreau K, Baker AL, Sundel RP, Newburger JW 1998 Coronary artery dimensions may be misclassified as normal in Kawasaki disease. J Pediatr 133: 254–258
Galis ZS, Khatri JJ 2002 Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90: 251–262
Pyo R, Lee JK, Shipley JM, Curci JA, Mao D, Ziporin SJ, Ennis TL, Shapiro SD, Senior RM, Thompson RW 2000 Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest 105: 1641–1649
Thompson RW, Parks WC 1996 Role of matrix metalloproteinases in abdominal aortic aneurysms. Ann N Y Acad Sci 800: 157–174
Gavin PJ, Crawford SE, Shulman ST, Garcia FL, Rowley AH 2003 Systemic arterial expression of matrix metalloproteinases 2 and 9 in acute Kawasaki disease. Arterioscler Thromb Vasc Biol 23: 576–581
Moon SK, Cha BY, Kim CH 2004 ERK1/2 mediates TNF-alpha-induced matrix metalloproteinase-9 expression in human vascular smooth muscle cells via the regulation of NF-kappaB and AP-1: involvement of the ras dependent pathway. J Cell Physiol 198: 417–427
Freestone T, Turner RJ, Coady A, Higman DJ, Greenhalgh RM, Powell JT 1995 Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 15: 1145–1151
Hui-Yuen JS, Duong TT, Yeung RS 2006 Tumour necrosis factor-alpha is necessary for induction of coronary artery inflammation and aneurysm formation in an animal model of Kawasaki disease. J Immunol 176: 6294–6301
Duong TT, Silverman ED, Bissessar MV, Yeung RS 2003 Superantigenic activity is responsible for induction of coronary arteritis in mice: an animal model of Kawasaki disease. Int Immunol 15: 79–89
Lehman TJ, Walker SM, Mahnovski V, McCurdy D 1985 Coronary arteritis in mice following the systemic injection of group B Lactobacillus casei cell walls in aqueous suspension. Arthritis Rheum 28: 652–659
Longo GM, Xiong W, Greiner TC, Zhao Y, Fiotti N, Baxter BT 2002 Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 110: 625–632
Senzaki H, Masutani S, Kobayashi J, Kobayashi T, Nakano H, Nagasaka H, Sasaki N, Asano H, Kyo S, Yokote Y 2001 Circulating matrix metalloproteinases and their inhibitors in patients with Kawasaki disease. Circulation 104: 860–863
Takeshita S, Tokutomi T, Kawase H, Nakatani K, Tsujimoto H, Kawamura Y, Sekine I 2001 Elevated serum levels of matrix metalloproteinase-9 (MMP-9) in Kawasaki disease. Clin Exp Immunol 125: 340–344
Chua PK, Melish ME, Yu Q, Yanagihara R, Yamamoto KS, Nerurkar VR 2003 Elevated levels of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 during the acute phase of Kawasaki disease. Clin Diagn Lab Immunol 10: 308–314
Chan WC, Duong TT, Yeung RS 2004 Presence of IFN-gamma does not indicate its necessity for induction of coronary arteritis in an animal model of Kawasaki disease. J Immunol 173: 3492–3503
Dubois M, Gilles KA, Hamilton JK, Rebers PA, Smith F 1958 Colorimetric method for determination of sugars and related substances. Anal Chem 28: 350–356
Lehman TJ, Warren R, Gietl D, Mahnovski V, Prescott M 1988 Variable expression of Lactobacillus casei cell wall-induced artertis: an animal model of Kawasaki's disease in selected inbred mouse strains. Clin Immunol Immunopathol 48: 108–118
McMillan WD, Tamarina NA, Cipollone M, Johnson DA, Parker MA, Pearce WH 1997 Size matters: the relationship between MMP-9 expression and aortic diameter. Circulation 96: 2228–2232
Allaire E, Forough R, Clowes M, Starcher B, Clowes AW 1998 Local overexpression of TIMP-1 prevents aortic aneurysm degeneration and rupture in a rat model. J Clin Invest 102: 1413–1420
Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP 1998 Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J 17: 1144–1148
Honkanen VE, McCrindle BW, Laxer RM, Feldman BM, Schneider R, Silverman ED 2003 Clinical relevance of the risk factors for coronary artery inflammation in Kawasaki disease. Pediatr Cardiol 24: 122–126
Curci JA, Mao D, Bohner DG, Allen BT, Rubin BG, Reilly JM, Sicard GA, Thompson RW 2000 Preoperative treatment with doxycycline reduces aortic wall expression and activation of matrix metalloproteinases in patients with abdominal aortic aneurysms. J Vasc Surg 31: 325–342
Franklin IJ, Harley SL, Greenhalgh RM, Powell JT 1999 Uptake of tetracycline by aortic aneurysm wall and its effect on inflammation and proteolysis. Br J Surg 86: 771–775
Bartoli MA, Parodi FE, Chu J, Pagano MB, Mao D, Baxter BT, Buckley C, Ennis TL, Thompson RW 2006 Localized administration of doxycycline suppresses aortic dilatation in an experimental mouse model of abdominal aortic aneurysm. Ann Vasc Surg 20: 228–236
Zaitsu M, Hamasaki Y, Tashiro K, Matsuo M, Ichimaru T, Fujita I, Tasaki H, Miyazaki S 2000 Ulinastatin, an elastase inhibitor, inhibits the increased mRNA expression of prostaglandin H2 synthase-type 2 in Kawasaki disease. J Infect Dis 181: 1101–1109
Acknowledgements
The authors thank Lily Morikawa, Lawrence Ng, and Erin Christie for technical assistance.
Author information
Authors and Affiliations
Corresponding author
Additional information
A.C.L. and H.R. contributed equally to this manuscript.
Rights and permissions
About this article
Cite this article
Lau, A., Rosenberg, H., Duong, T. et al. Elastolytic Matrix Metalloproteinases and Coronary Outcome in Children with Kawasaki Disease. Pediatr Res 61, 710–715 (2007). https://doi.org/10.1203/pdr.0b013e318053418b
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1203/pdr.0b013e318053418b
This article is cited by
-
Comparative effectiveness of intravenous immunoglobulin from different manufacturing processes on Kawasaki disease
World Journal of Pediatrics (2014)
